Migraine (chronic) - botulinum toxin type A: final appraisal determination
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on Botulinum toxin type A for the prophylaxis of headaches associated with chronic migraine and submitted it to the Institute.
The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.
Please note that the appeal period for this appraisal will close at 5pm on 25 May 2012.
Migraine (chronic) - botulinum toxin type A: final appraisal determination
Migraine (chronic) - botulinum toxin type A: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
Migraine (chronic) - botulinum toxin type A: consultee and commentator comments on the ACD
Migraine (chronic) - botulinum toxin type A: comments on the ACD received from the public through the NICE website
Migraine (chronic) - botulinum toxin type A: additional evidence submitted by Allergan
Migraine (chronic) - botulinum toxin type A: Evidence Review Group critique of additional evidence
Migraine (chronic) - botulinum toxin type A: Allergan response to request for additional clarification
Migraine (chronic) - botulinum toxin type A: Evidence Review Group critique of Allergan response to request for additional evidence
This page was last updated: 02 January 2015